And then there were … oh, forget it: We’ve given up trying to count the number of CRISPR companies, but we can tell you that one more came out of stealth mode on Thursday. After a year spent wooing investors, hiring, and refining its plans, Mammoth Biosciences, co-founded by CRISPR developer Jennifer Doudna, is announcing its entry into the ever-more-crowded fields of diagnostics and genome-editing, and hoping to find a sweet spot at their intersection.
“Mammoth Biosciences is all about building a CRISPR-based platform for disease detection,” said CEO Trevor Martin, who got a Ph.D. in genetics and statistics from Stanford in 2016.
The company’s point-of-care test on urine, saliva, blood, or sweat will work like a home pregnancy kit, disposable paper strip and all; be able to test for several conditions at a time; and return results (a color change) in 30 minutes. It has an experimental prototype, and hopes to reach the market “in the next few years,” Martin said.
About the Author Reprints
